Highly efficient synthesis of rosuvastatin intermediate using a carbonyl reductase–cofactor co‐immobilized biocatalyst in the non‐aqueous biosystem
Xiao‐Jian Zhang,Di Wu,Wen‐Zhong Wang,Min Cao,Qian Liu,Zhi‐Qiang Liu,Yu‐Guo Zheng
DOI: https://doi.org/10.1002/jctb.6861
IF: 3.709
2021-08-03
Journal of Chemical Technology and Biotechnology
Abstract:BackgroundNon-aqueous biocatalytic system has exhibited advantages including outstanding substrate solubility, facilitation of product purification, suppression of unwanted water-dependent side reactions, rare wastewater discharge etc. However, limited by enzyme stability, selectivity, and cofactor recycling, there was no successful attempt of carbonyl reductases in the non-aqueous phase. ResultsIn this study, the non-aqueous catalytic system of carbonyl reductase was developed for the first time with a carboyl reductase-cofactor co-immobilized biocatalyst. Using n-hexane as the reaction medium, the key chiral diol intermediate of the top selling hypolipidemic drug rosuvastatin, tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate ((3R,5S)-CDHH) was prepared in a continuous packed-bed bioreactor with the total yield of 95.51%, enantiomeric excess (e.e.) > 99.5% and diastereomeric excess (d.e.) > 99.5% in a 44-batch reaction. The yield of per unit biocatalyst was 34.42 mg/U, and the space-time yield was 91.01 g/h/L. ConclusionOur work corroborated the valuable prospect of carbonyl reductases in non-aqueous biosynthesis of chiral pharmaceuticals and fine chemicals.This article is protected by copyright. All rights reserved.
engineering, chemical,biotechnology & applied microbiology, environmental,chemistry, multidisciplinary